Dokkyo Medical University Hospital(6.5 mi away)Contact
+37 other location
The purpose of this study is to evaluate the efficacy of ustekinumab in participants with
active polymyositis (PM)/dermatomyositis (DM) despite receiving 1 or more standard-of-care
treatments (for example, glucocorticoids and/or immunomodulators).
Ustekinumab 90 mg,
Ustekinumab 6 mg/kg
Clinical Study Identifier
Janssen Pharmaceutical K.K.
Last Modified on
31 December 2020
How clear was the trial content above?
Adding a note
Select a piece of text and start making personal notes.
If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.
Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.